Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Vertex Pharmaceuticals
So what: The trial showed that lung function improved more than 10% in patients with cystic fibrosis, exceeding expectations that analysts had put on the drug. This is a big step forward and sets the stage for the company to seek U.S. and European approval in the second half of 2011.
Now what: Analysts think that VX-770 could generate more than $500 million in sales, but that was before today's outstanding results. This Motley Fool Rule Breakers pick is truly breaking all the rules with this drug and if approved should lead to more gains for Vertex. I am bullish on the results and Vertex's solid pipeline of new drugs helping push the stock higher.
Interested in more info on Vertex Pharmaceuticals? Add it to your watchlist.